Literature DB >> 29106064

Chemical profiling and quantification of ShenKang injection, a systematic quality control strategy using ultra high performance liquid chromatography with Q Exactive hybrid quadrupole orbitrap high-resolution accurate mass spectrometry.

Tanye Xu1, Lihua Zuo1, Zhi Sun1, Peile Wang1, Lin Zhou1, Xiaojing Lv1, Qingquan Jia1, Xin Liu1, Xiaofang Jiang1, Zhenfeng Zhu1, Jian Kang1, Xiaojian Zhang1.   

Abstract

ShenKang injection is traditional Chinese medicine used to treat chronic renal failure in China. It is a compound preparation that consists of four herbs: Rhubarb, Salvia miltiorrhiza, Safflower and Radix Astragali. We developed an ultra high pressure liquid chromatography coupled with Q Exactive hybrid quadrupole-orbitrap high resolution accurate mass spectrometry tandem mass spectrometry method to analyze its chemical compositions, and a total of 90 compounds were identified from ShenKang injection. Among them, 19 major compounds were unambiguously detected by comparing with reference standards. Meanwhile, 13 representative compounds selected as quality control markers were simultaneously quantified in ShenKang injection samples. Chromatographic separation was accomplished on a Waters ACQUITY HPLC® HSS C18 column using gradient elution. The method was validated with respect to linearity, sensitivity, accuracy and precision, reproducibility and stability. And the validated method was successfully applied for simultaneous determination of 13 bioactive compounds in ShenKang injection from ten batches of samples by liquid chromatography with mass spectrometry. The results were analyzed by principal components analysis method, and three compounds had a significant relationship with the quality control of ShenKang injection. This research established a rapid and reliable method for the integrating quality control, including qualitation and quantification of ShenKang injection.
© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  ShenKang injection; chemical profiling; quality control; tandem mass spectrometry; traditional Chinese medicine

Mesh:

Substances:

Year:  2017        PMID: 29106064     DOI: 10.1002/jssc.201700928

Source DB:  PubMed          Journal:  J Sep Sci        ISSN: 1615-9306            Impact factor:   3.645


  5 in total

1.  Shenkang Injection for Treating Renal Fibrosis-Metabonomics and Regulation of E3 Ubiquitin Ligase Smurfs on TGF-β/Smads Signal Transduction.

Authors:  Junju Zou; Xiaotao Zhou; Xian Chen; Yuerong Ma; Rong Yu
Journal:  Front Pharmacol       Date:  2022-06-02       Impact factor: 5.988

2.  ShenKang Injection Attenuates Renal Fibrosis by Inhibiting EMT and Regulating the Wnt/β-Catenin Pathway.

Authors:  Hui-Ting Wei; Yuan Xu; Xiao-Yang Tan; Hao-Yue Jing; Yue-Rong Ma
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-28       Impact factor: 2.650

3.  Systematic Profiling of the Multicomponents and Authentication of Erzhi Pill by UHPLC/Q-Orbitrap-MS Oriented Rapid Polarity-Switching Data-Dependent Acquisition and Selective Monitoring of the Chemical Markers Deduced from Fingerprint Analysis.

Authors:  Li Jia; Lingling Fu; Xiaoyan Wang; Wenzhi Yang; Hongda Wang; Tiantian Zuo; Chunxia Zhang; Ying Hu; Xiumei Gao; Lifeng Han
Journal:  Molecules       Date:  2018-11-30       Impact factor: 4.411

4.  HPLC-MS and Network Pharmacology Analysis to Reveal Quality Markers of Huo-Xue-Jiang-Tang Yin, a Chinese Herbal Medicine for Type 2 Diabetes Mellitus.

Authors:  Qiugu Chen; Yuan Zhao; Maosheng Li; Ping Zheng; Shangbin Zhang; Huilin Li; Jianping Chen
Journal:  Evid Based Complement Alternat Med       Date:  2021-03-15       Impact factor: 2.629

5.  Shenkang injection improves chronic kidney disease by inhibiting multiple renin-angiotensin system genes by blocking the Wnt/β-catenin signalling pathway.

Authors:  Yan-Ni Wang; Hong-Jiao Liu; Li-Li Ren; Ping Suo; Liang Zou; Ya-Mei Zhang; Xiao-Yong Yu; Ying-Yong Zhao
Journal:  Front Pharmacol       Date:  2022-08-17       Impact factor: 5.988

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.